Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

Anavex Life Sciences (Nasdaq: AVXL) received an expected Nasdaq delinquency notification on May 20, 2026, for not timely filing its Form 10-Q for the quarter ended March 31, 2026.

Rhea-AI Summary

Anavex Life Sciences (Nasdaq: AVXL) received an expected Nasdaq delinquency notification on May 20, 2026, for not timely filing its Form 10-Q for the quarter ended March 31, 2026.

The company has until July 20, 2026 to submit a compliance plan and states the notice has no immediate effect on its Nasdaq listing.

Positive

• Nasdaq granted Anavex until July 20, 2026 to submit a compliance plan
• Company states the delinquency notification has no immediate effect on its Nasdaq-listed common stock
• Anavex reports it is working to complete and file the delayed Form 10-Q

Negative

• Anavex is not in compliance with Nasdaq Listing Rule 5250(c)(1)
• Company did not timely file its Form 10-Q for quarter ended March 31, 2026
• Receipt of Nasdaq delinquency notification highlights a filing delay and listing-rule deficiency

Argus May 22 session

-0.55% close to close Open Argus

Details

News Market Reaction – AVXL

On May 22, the day this news came out, AVXL closed 0.55% below the previous close.

Data tracked by StockTitan Argus for the May 22 session.

Key Figures

Form 10-Q period end: March 31, 2026 Nasdaq rule: Listing Rule 5250(c)(1) Notice date: May 20, 2026 +5 more

Form 10-Q period end

March 31, 2026

Quarterly report referenced in Nasdaq delinquency notice

Nasdaq rule

Listing Rule 5250(c)(1)

Rule cited for timely filing non-compliance

Notice date

May 20, 2026

Date Nasdaq delinquency notification letter was received

Compliance plan deadline

July 20, 2026

Deadline to submit plan to regain Nasdaq compliance

Current price

$2.71

Price before publication of delinquency notice press release

52-week high

$13.99

High preceding the delinquency notice

52-week low

$2.61

Low preceding the delinquency notice

1-day price change

-1.45%

Move in the 24 hours prior to this news

Historical Context

5 past events · Latest: May 06

5 events

1. May 06

   Leadership change, filing delay

   24h Move

   -0.6%

   CEO termination, interim CEO appointment, and signaled Form 10-Q delay.

2. Apr 14

   Scientific findings update

   24h Move

   +0.3%

   New data linking autism and Alzheimer’s supporting blarcamesine rationale.

3. Apr 07

   Conference participation

   24h Move

   +4.0%

   Announcement of presentation at Needham Virtual Healthcare Conference.

4. Mar 30

   Regulatory pathway update

   24h Move

   +0.0%

   Comprehensive regulatory update including EU withdrawal and FDA data submission.

5. Mar 25

   EU filing withdrawal

   24h Move

   -34.6%

   Withdrawal of EU marketing application after CHMP indicated no positive opinion.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 10-q, nasdaq listing rule 5250(c)(1), delinquency notification letter, listing qualifications department, +1 more

5 terms

form 10-q regulatory

"timely file its Form 10-Q for the quarterly period ended March 31, 2026."

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

nasdaq listing rule 5250(c)(1) regulatory

"not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”)"

Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.

delinquency notification letter regulatory

"announced it received an expected delinquency notification letter (the “Notice”)"

A delinquency notification letter is a formal notice sent by a lender or servicer to a borrower informing them that a scheduled payment has been missed and outlining next steps, fees, or deadlines to cure the delinquency. For investors, these letters signal higher credit risk in a loan portfolio—like a red flag on a borrower’s payment behavior—and can foreshadow reduced cash flow, higher collection costs, or eventual default that affect returns.

listing qualifications department regulatory

"from the Listing Qualifications Department of The Nasdaq Stock Market LLC"

A listing qualifications department is the part of a stock exchange that checks whether a company meets the exchange’s rules for being listed and staying listed. Think of it as a gatekeeper or building inspector: it reviews financial statements, disclosure practices and corporate governance, flags problems and can require fixes or remove a company’s shares. Investors care because its decisions affect whether a stock remains tradable and how much trust to place in a company’s reporting.

the nasdaq stock market llc regulatory

"from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)"

The Nasdaq Stock Market LLC is a major U.S. stock exchange that provides the platform and rules for buying and selling shares of public companies, similar to a busy online marketplace where buyers and sellers meet. It matters to investors because it determines where a stock trades, helps set prices through supply and demand, and enforces listing and reporting standards that affect a company’s visibility, liquidity and regulatory oversight.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company’s inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026.

As indicated in the Notice, the Company has until July 20, 2026, to submit a plan to regain compliance. The Company is working prudently to complete and file the Form 10-Q and submit a plan to regain compliance with the Nasdaq Listing Rule.

This notification has no immediate effect on the Company’s common stock listed on Nasdaq.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Further information is available at www.anavex.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating to the Company’s plans to complete and file its Form 10-Q and to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1). These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited to, risks related to the Company’s ability to file the Form 10-Q and the Company’s ability to regain compliance with Nasdaq Listing Rule 5250(c)(1) and other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent filings and furnishings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.

Investor Relations & Media Contact:

SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com

Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com

Company Contact:

Sandra Boenisch
Principal Financial Officer
Anavex Life Sciences Corp.
Tel: 1-844-689-3939
Email: ir@anavexcorp.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Anavex Life Sciences (AVXL) receive a Nasdaq delinquency notification in May 2026?

Anavex received the notification because it did not timely file its Form 10-Q for the quarter ended March 31, 2026. According to Anavex, this delay caused non-compliance with Nasdaq Listing Rule 5250(c)(1), prompting the Listing Qualifications Department to issue the delinquency notice.

What does the Nasdaq Listing Rule 5250(c)(1) issue mean for Anavex (AVXL) investors?

The issue means Anavex is currently not compliant with Nasdaq’s timely periodic reporting requirement after missing its Form 10-Q filing. According to Anavex, the delinquency notification has no immediate effect on its common stock listing while it works on regaining compliance.

What deadline did Nasdaq give Anavex (AVXL) to regain listing compliance?

Nasdaq gave Anavex until July 20, 2026 to submit a plan to regain compliance with Listing Rule 5250(c)(1). According to Anavex, it is working to complete and file the Form 10-Q and provide Nasdaq with a compliance plan by that date.

Does the Nasdaq delinquency notification immediately affect Anavex (AVXL) stock trading?

According to Anavex, the Nasdaq delinquency notification has no immediate effect on its common stock listed on Nasdaq. Trading in AVXL shares continues while the company prepares its delayed Form 10-Q and a compliance plan for submission by July 20, 2026.

How is Anavex (AVXL) responding to the Nasdaq delinquency notice about its Form 10-Q?

Anavex reports it is working prudently to complete and file the Form 10-Q for the quarter ended March 31, 2026. According to Anavex, it also intends to submit a detailed plan to Nasdaq by July 20, 2026 to regain compliance.